Clinical Trial Update: A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer [Phase 1]

View source ↗

Summary

Phase I clinical trial evaluating an autologous dendritic cell vaccine in patients with recurrent ovarian cancer or primary peritoneal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Autologous dendritic cell vaccine (dendritic cell vaccine)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Ovarian Cancer, Peritoneal Cancer | Phase 1 | Status: COMPLETED